Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

significant proportion of infected individuals, leading to cirrhosis, primary liver cancer, and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon(R) for hepatitis C, and LymphoStat-B(R) for lupus. Phase 3 clinical trials of both compounds are now underway.

In June 2006, HGS announced that the U.S. Government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) for the treatment of anthrax disease. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of hematopoietic and solid malignancies, in addition to an antibody to the CCR5 receptor for the treatment of HIV/AIDS.

For more information about HGS, please visit the Company's web site at www.hgsi.com. For more information about Albuferon, please visit http://www.hgsi.com/products/albuferon.html. Health professionals or patients interested in Albuferon clinical trials or other studies involving HGS products may inquire via the Contact Us section of the Company's web site, www.hgsi.com/products/request.html, or by calling us at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... Diabetes Institute (WDI) at Western University of Health Sciences to learn more about ... of Periodontology, School of Dental Sciences and Institute of Cellular Medicine at Newcastle ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... CDA Press, the expert guest author addressed the topic of treating back pain caused ... that, while steroids were shown to slightly improve physical function in patients suffering from ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law firm of ... been nominated by his peers to earn a “Leading Lawyers” distinction. ... in the state of Illinois. The nomination process is based on statewide peer survey ...
(Date:8/31/2015)... Michigan (PRWEB) , ... August 31, 2015 , ... ... pre and postnatal fitness classes. , Starting September 1st they are ... called "The Mom Bod" and "Healthy Body, Healthy Baby." , More information can ...
(Date:8/31/2015)... ... 2015 , ... Coast Dental Vista is celebrating its recent grand ... 3 p.m. near Albertsons in the Foothill Center, located at 1279 E. Vista Way. ... Dr. Jay Lopp. Call (760) 208-2518 for more details or stop by on September ...
Breaking Medicine News(10 mins):Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3
... potential to alter voice characteristics. One solution for sleep apnoea ... night - is to remodel the nasal and throat cavity ... a flap of tissue at the top of the throat ... - in an operation called uvulopalatopharyngoplasty (UPPP) - the shape ...
... sense of humour has nothing to do with your genes, and ... traits such as being introverted or extroverted are believed to be ... applied to our sense of humour. ,The team asked 71 ... go into separate rooms and rate five cartoons on a scale ...
... Healthy, hearing babies born to deaf parents and exposed ... ``babble,'' indicating that babbling serves as an important precursor ... a professor in the departments of Psychological & Brain ... Hampshire believes, that this must be the key that ...
... new bacterial genome sequence suggests a route to new ... evade antibiotics, even minor infections can become a major ... to tackle resistant bacteria.// ,Antibiotic resistance is a ... antibiotics come from the soil bacteria Streptomyces , including ...
... According to a research obese heart patients live on ... overweight also hastens the onset of heart disease by ... stay slim. ,It has long been known ... from Duke University Medical Center, North Carolina, have become ...
... released by the Institute for the Study of Aging and ... stay mentally agile are better advised to put down the ... shows that seniors who do crossword puzzles, exercise and seek ... who put their trust in unproven cures such as melatonin, ...
Cached Medicine News:
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: